- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00414752
Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking
June 21, 2007 updated by: Novartis
A Randomized, Double Blind, Multiple Dose, Cross-Over, Placebo- and Active-Controlled Proof of Concept Study to Explore the Effects of AFQ056 and Nicotine (Active Comparator) on Craving and Withdrawal During Voluntary Smoking Abstinence in Healthy Smokers
The purpose of this study is to assess the safety and efficacy of AFQ056 and nicotine compared to placebo on craving and withdrawal symptoms during voluntary smoking stoppage in healthy smokers.
This study will also assess how the body interacts with AFQ056.
Study Overview
Study Type
Interventional
Enrollment
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nuernberg, Germany
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, male & female subjects at least 18 years and ≤60 years of age
- In good health
- Female subjects must be surgically sterilized or postmenopausal.
- Current smokers not intending to quit
- Smoke on average 15 cigarettes or more and less than 60 cigarettes a day for the past year
- Fagerström Test for Nicotine Dependence score of at least 5 (indicates moderate to heavy smokers)
- Willing to refrain from smoking as required
- Written informed consent before entering the study
Exclusion Criteria:
- History of heart disease, septum defect and/or cardiac valves surgery; clinical relevant abnormality in the ECG
- Investigational drug treatment within 4 weeks prior to screening unless local health authority guidelines mandate a longer period
- Women of childbearing potential, pregnant or lactating females
- Donation of one unit (400mL) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 months or a blood transfusion within 8 weeks prior to screening.
- Coffee consumption of more than 6 cups coffee/day
- Use of a medication within 2 weeks prior to Day 1 of each treatment period
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction of craving by self-report questionnaires during 3 days of voluntary smoking stoppage
|
Secondary Outcome Measures
Outcome Measure |
---|
Reduction in symptoms of withdrawal during 3 days of voluntary smoking stoppage
|
Reduction in nicotine consumption during 6 days of free smoking
|
Reduction in impulsivity during 3 days of free smoking and during 3 days of voluntary smoking stoppage
|
Reduction in craving during 6 days of free smoking
|
Safety and tolerability of AFQ056 during treatment periods
|
Assessment of how the body interacts with AFQ056
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Study Registration Dates
First Submitted
December 21, 2006
First Submitted That Met QC Criteria
December 21, 2006
First Posted (Estimate)
December 22, 2006
Study Record Updates
Last Update Posted (Estimate)
June 22, 2007
Last Update Submitted That Met QC Criteria
June 21, 2007
Last Verified
June 1, 2007
More Information
Terms related to this study
Other Study ID Numbers
- CAFQ056A2109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Abstinence
-
Sir Run Run Shaw HospitalPfizerUnknownSmoking Abstinence | Smoking Cessation InterventionChina
-
University of MinnesotaNational Institutes of Health (NIH)CompletedSmoking Abstinence | HRT | Non-HRT | Continued Smoking
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Enrolling by invitationSmoking Cessation | Smoking AbstinenceUnited States
-
University of Alabama at BirminghamNational Institute on Drug Abuse (NIDA)CompletedSmoking Reduction or AbstinenceUnited States
-
Philip Morris Products S.A.CompletedSmoking | Inflammation | Oxidative Stress | Smoking AbstinenceJapan, Germany, Czechia, Greece
-
Yale UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Tobacco AbstinenceUnited States
-
Alternatives For GirlsRecruitingAbstinence, SexUnited States
-
IVI BilbaoInstituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
University of UtahRecruitingMethamphetamine-dependence | Postpartum AbstinenceUnited States
-
Ajna HamidovicCompletedTobacco Abstinence SyndromeUnited States